Radiopharm Theranostics Limited

RADX | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.61

-$0.04 (-2.42%)

At close: Sep 21, 2026, 4:00 PM ET

$1.61

$0 (0.00%)

After-hours: Sep 21, 2026, 4:10 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-2.42%

(1D)

Rating

Updated: Aug 14, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $2.07M

1D Range

1.60 1.73

52W Range

1.50 16.25

Valuation (TTM)

PE 0

PB 0.12

EV/EBITDA 0.02

Valuation (NTM)

Forward PE N/A

Forward PEG 0.12

Price Target $6

Cash Flow

FCF Yield -764.2%

SBC Adj. FCF Yield -764.2%

SBC Impact N/A

Margins

Gross Margin -39.4%

Operating Margin -2550.7%

FCF Margin -805.8%

Growth (CAGR)

Revenue 3Y | 5Y 110.0% | N/A

Dil EPS 3Y | 5Y 102.9% | N/A

FCF 3Y | 5Y 57.8% | N/A

Returns

ROA -91.7%

ROE -144.2%

ROIC -158.1%

Financial Health

Net Cash

A$4.14M ($2.86M)

Current Ratio 1.16

Interest Coverage -626.93

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to a...

Sector Healthcare

Industry Biotechnology

Employees 14

IPO Date Dec 4, 2024

Website www.radiopharmtheranostics.com

Fiscal Year July - June

Full Company Profile

Latest News

No news articles available yet.

Earnings

Latest Earnings

Aug 28, 2026

EPS

-$1.20

Beat +28.73%

YoY: +32.82%

REV

$699.25K

Miss -17.27%

YoY: -52.91%

Next Earnings

Feb 26, 2027

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+272.67%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞